Covid-long pathology affects a large number of patients, and represents a major medical,economic and societal challenge. To date, we have no objective criterion for a definitivediagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based onrecruitment from the infectious diseases department of Nice University Hospital, theinvestigator's team wants to conduct an innovative pathophysiological study to betterdefine the disease and identify specific biomarkers that could subsequently be used as adiagnostic tool for Covid-long. 120 participants will be initially included for the modellearning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.
Not Provided
Procedure: Brain MRI
non injected brain MRI
Biological: Specific blood samples
blood samples to find immunological and inflammatory markers
FOR CL+ PATIENTS
Inclusion Criteria:
- Case definition in line with WHO Delphi process
Exclusion Criteria:
- History of chronic fatigue syndrome diagnosed before or after Covid.
- History of progressive psychiatric pathology.
- History of acute Covid requiring admission to intensive care and mechanical
ventilation.
- No social security affiliation.
FOR CONTROL (CL-)
Inclusion Criteria:
- History of acute COVID-19, mild, moderate or severe (episode at least 3 months at
the time of inclusion).
- Absence of persistent symptoms more than 3 months after first Covid symptoms (or
mild not affecting daily activities).
Exclusion Criteria:
- History of progressive psychiatric pathology.
- History of acute Covid requiring admission to intensive care and mechanical
ventilation.
- No social security affiliation.
- Pregnant or breast-feeding.
CHU de NICE
Nice, France
Michel CARLES, PhD
04 92 03 55 15
carles.m@chu-nice.fr
Irit TOUITOU
04 92 03 58 47
touitou.i@chu-nice.fr
Not Provided